Press release
Comprehensive Neupogen (filgrastim) Market Insights: Forecasting Size, Growth, and Competitive Trends from 2025 to 2034
Neupogen filgrastim Market
The advancement of the neupogen (filgrastim) market is anticipated due to an escalating occurrence of diverse diseases. Diseases refer to irregularities in bodily functions or structures that manifest particular symptoms and commonly impact specific areas, generally induced by environmental factors, lifestyle choices, infections, or genetics. The escalating prevalence of diseases is propelled by elements like an aging populace, rising contamination levels, sluggish lifestyles, global spread of infectious diseases, and poor eating habits. Neupogen (filgrastim) offers a solution for the complicated issues of neutropenia resulting from chemotherapy by encouraging the creation of neutrophils, thereby reinforcing the ability of the immune system to deter infections in those with vulnerable immunity. This is key in lowering hospitalization rates, managing infection risks, and enabling unhampered cancer treatment schemes for patients under intense therapies. For example, as per Allergy UK, a national charity based in the UK, over 21 million individuals in the UK were allergy-affected in April 2024, turning allergies into the most frequently reported persisting health issue in 2022, with forecasts suggesting that by 2026, one allergy will be experienced by half of Europe's population. Similarly, according to UK-based cancer charity Macmillan Cancer Support, the count of people dealing with cancer touched 3 million in 2022 and is estimated to escalate to nearly 3.5 million by 2025 and 4 million by 2030 in the UK as per data released in June 2022. Hence, the escalating prevalence of diverse diseases is fuelling the advancement of the neupogen (filgrastim) market. Furthermore, the surge of the neupogen (filgrastim) market is also anticipated due to the development initiatives in healthcare backed by governments. Government actions, referring to strategies, projects, programs, or specific measures initiated by government bodies at various layers including local, regional, national, and international, are targeted at resolving precise issues, achieving certain goals or enhancing societal conditions. Various government bodies are launching several healthcare measures supporting different aspects along with neupogen (filgrastim). For instance, as per the Department of Health and Social Care, a governmental body based in the UK, the UK government voiced in 2022 an allocation of £260 million (equivalent to US $270.65 million) for intensifying healthcare research and manufacturing. This allocation announced by BEIS and DHSC was meant for buttressing NHS-led health research related to treatment and diagnostics via new platforms safeguarding privacy and clinical research services, and £60 million (amounting to US $63.60 million) for augmenting life sciences manufacturing in the UK. Therefore, government-backed development initiatives in healthcare are fueling the neupogen (filgrastim) market.
Get Your Neupogen (filgrastim) Market Report Here:
https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-
What growth opportunities are expected to drive the neupogen (filgrastim) market's CAGR through 2034?
The market size for neupogen (filgrastim) has seen significant expansion in the past few years. Projections indicate that it will increase from $1,330.69 million in 2024 to $1,404.70 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.6%. Factors contributing to this growth during the historic period include a rise in cancer cases, enhanced awareness regarding chemotherapy-induced neutropenia, advancements in healthcare infrastructure, early green light for Neupogen biosimilars, and an increase in worldwide healthcare expenditure.
In the forthcoming years, the neupogen (filgrastim) market is projected to witness robust growth, expanding to $1,727.05 million in 2029 with a compound annual growth rate (CAGR) of 5.3%. The anticipated growth over the forecast span can be attributed to escalating demand for affordable neutropenia treatments, expansion of healthcare facilities in developing markets, increased government initiatives in promoting biosimilar uptake, a heightened emphasis on personalized medications, and an aging population. Key trends in the forecast span incorporate growing investments in research and development of biosimilars, advances in neutropenia treatment delivery systems, increasing collaborations for the commercialization of cancer drugs, a greater emphasis on patient affordability schemes, and the creation of advanced G-CSF products.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19910&type=smp
What are the emerging trends shaping the future of the neupogen (filgrastim) market?
A crucial transformation in the market for Neupogen (filgrastim) involves the emphasis on creating cutting-edge filgrastim biosimilar alternatives that are economical and accessible for chemotherapy-induced neutropenia patients. Filgrastim biosimilar solutions are biological medications that essentially resemble Neupogen (filgrastim) in their safety, efficiency, and composition, chiefly used to enhance the generation of neutrophils in patients receiving chemotherapy to prevent neutropenia. For instance, Releuko (filgrastim-ayow), a Neupogen (filgrastim) referenced biosimilar, was introduced into the US market in November 2022 by Amneal Pharmaceuticals and Kashiv Biosciences, both US-based companies. The unique feature of Releuko includes both intravenous and subcutaneous versions available in individual dose vials and prefilled syringes, allowing healthcare providers flexibility in administration. It signifies its importance by offering an affordable treatment path for chemotherapy-induced neutropenia, increasing the accessibility of vital oncology care, and meeting the escalating demand for biosimilars in the market.
Which growth-oriented segments of the neupogen (filgrastim) market are leading the industry's development?
The neupogen (filgrastim)market covered in this report is segmented -
1) By Drug Type: Biologic; Biosimilar
2) By Indication: Chemotherapy Induced Neutropenia; Chronic Neutropenia; Others
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/Discount?id=19910&type=discount
What regions are leading the charge in the neupogen (filgrastim) market?
North America was the largest region in the neupogen (filgrastim) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What companies are at the forefront of innovation in the neupogen (filgrastim) market?
Major companies operating in the neupogen (filgrastim) market include Amgen Inc.
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=19910&type=smp
What Is Covered In The Neupogen (filgrastim) Global Market Report?
•Market Size Forecast: Examine the neupogen (filgrastim) market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the neupogen (filgrastim) market for a structured understanding.
•Key Players Overview: Analyze major players in the neupogen (filgrastim) market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the neupogen (filgrastim) market.
•Segment Contributions: Evaluate how different segments drive overall growth in the neupogen (filgrastim) market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the neupogen (filgrastim) market.
•Industry Challenges: Identify potential risks and obstacles affecting the neupogen (filgrastim) market.
•Competitive Landscape: Review strategic developments in the neupogen (filgrastim) market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Comprehensive Neupogen (filgrastim) Market Insights: Forecasting Size, Growth, and Competitive Trends from 2025 to 2034 here
News-ID: 3937654 • Views: …
More Releases from The Business Research Company
Company Registration Service Market Landscape 2025: Forecast Data and Growth Str …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Company Registration Service Market Through 2025?
The market size for company registration services has seen robust growth in the recent past. The market is projected to expand from $10.67 billion in 2024 to $11.55 billion in 2025, exhibiting a compound annual growth…
Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecast …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Toilet Partition Market Through 2025?
In recent years, the market size for commercial toilet partitions has significantly expanded. The forecast predicts a rise from $1.82 billion in 2024 to $1.95 billion in 2025, with a compound annual growth rate (CAGR) of…
Key Trends Influencing the Growth of the Commercial Insurance For Small And Medi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market Through 2025?
The market size of commercial insurance for small and medium-sized enterprises (SMEs) has seen substantial growth over the recent years. A rise from $111.83 billion in 2024 to $119.76 billion in…
Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Combustion Emissions Analyzer Market Through 2025?
In the past few years, the market size for combustion emissions analyzer has seen robust growth. It is projected to increase from $1.02 billion in 2024 to $1.09 billion in 2025, with a compound annual growth…
More Releases for Neupogen
Neupogen Market Expansion Fueled by Cancer Supportive Care and Neutropenia Treat …
The qualitative latest Research report (2025-2032) on the Neupogen Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves.
Request a Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/8115
Focused on growth and future…
Neupogen Market Set to Witness Significant Growth from 2025 to 2032, Highlightin …
The Neupogen Market 2025 Forecast to 2032" research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The market report also examines the current state of the Neupogen industry, as well as predicted future growth, technological advancements, investment prospects, market economics, and financial…
Neupogen Market Surging as Biosimilars Take Over and Supportive Cancer Care Expa …
The Global Neupogen Market is expected to decline from USD 89.2 Mn in 2025 to USD 30.5 Mn by 2032, with a negative CAGR of -14.2% over the forecast period.
The latest Neupogen Market research report offers crucial insights into how the industry is evolving, highlighting key drivers of growth and the main revenue streams expected between 2025 and 2032. It analyzes market size, revenue, production, and CAGR using validated…
Neupogen (filgrastim) Market Outlook 2025-2034: Key Trends, Growth Drivers, and …
How Big Is the Neupogen (filgrastim) Market Expected to Be, and What Will Its Growth Rate Be?
In the recent past, the market size of neupogen (filgrastim) has seen a significant surge. The sector is expected to boost from $1,330.69 million in 2024, reaching up to $1,404.70 billion in 2025 with a compound annual growth rate (CAGR) of 5.6%. Factors such as a surge in cancer cases, increased understanding of chemotherapy-induced…
Biosimilar Competition Market 2019 |Is Heating-up! Have You Mapped Your Competit …
Biosimilar approvals have increased steeply in the recent years. Europe leads in terms of biosimilar approvals. However, the U.S. has also shown significant growth in terms of biosimilar approvals. Sandoz’s Zarxio, a biosimilar to Amgen’s bone marrow stimulant Neupogen (filgrastim) — was the first biosimilar approved in the U.S., followed by three approvals in 2016. The number has increased to nine in 2017 and hit a record number of 16…
Global Filgrastim biosimilar market is expected to grow at rapid pace with stron …
InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on ' Global Filgrastim Biosimilar Market Assessment – Revenue Forecast, Clinical Trial/Pipeline Analysis, Brand/Originator Drug Historic Revenue and Forecast Till 2027'
Request for ToC/Proposal: https://bit.ly/2UNpfGA
Filgrastim is G-CSF that stimulates bone marrow to produce more neutrophils. The drug was developed by Amgen and marketed under the trade name of Neupogen. It was approved in the U.S. by Food Drug and Administration…
